15 August 2008
AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
AstraZeneca today announced an innovative new partnership with the National Cancer Centre Singapore (NCCS) and the National University Hospital (NUH) to develop anti-cancer compounds.

27 May 2008
Study of Twins Reveals Genetic Susceptibility to Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca and Karolinska Institutet scientists present data at American Thoracic Society International Conference.

23 May 2008
AstraZeneca and Dainippon Sumitomo Collaboration Yields Novel Therapeutic Agent for Respiratory Disorders
AstraZeneca today announced progression to clinical development of a novel therapeutic agent for allergic disorders, discovered in collaboration with Dainippon Sumitomo Pharma (DSP).

23 April 2008
The importance of scientific research – Jan Lundberg and Nobel Prize Laureates at the Stockholm Meeting 2008
Jan Lundberg was one of the speakers at the Stockholm Meeting 2008 – From Nobel Prize to commercial use and improved daily life.

8 April 2008
Making progress
In 2007 we made tremendous progress with our pipeline. This success has also received external recognition as we were awarded the R&D Directions "Best Early Stage Pipeline" in the industry for the second year in a row.

19 March 2008
Jan Lundberg interview with "The Pink Sheet" DAILY
In this article Jan Lundberg, AstraZeneca Executive VP, Head of Global Discovery Research, sat down with "The Pink Sheet" DAILY last month in Washington, D.C.

24 January 2008
John Patterson interview with Pharmaceutical Executive
In this article John Patterson, Executive Director Development, talks to Pharmaceutical Executive answering questions regarding improvements to our pipeline and the increasing number of projects in our portfolio.

2 January 2008
John Patterson interview with Pharmafocus
John Patterson, AstraZeneca Executive Director, Development, was recently interviewed by Pharmafocus, where he spoke about the rigorous work that has been put into simultaneously improving the quality, cost and speed of AstraZeneca's drug development process

10 December 2007
Behind the Nobel Peace Prize – The work of many scientists
The vital work of making asthma inhalers less damaging to the ozone layer has earned an AstraZeneca scientist two major honours – including a share in the 2007 Nobel Peace Prize.

18 October 2007
AstraZeneca a Top Employer as voted in Science Magazine's annual survey

23 March 2007
AstraZeneca Names Shanghai Site As Initial Base for New Innovation Centre China
AstraZeneca today announced Shanghai’s Zhangjiang Hi-Tech Park as the initial base for its new Innovation Centre China (ICC).

21 March 2007
AstraZeneca Inaugurates State-of-the-Art Global Process R&D lab in Bangalore
This facility will strengthen the existing global PR&D programmes as well as provide support to the existing Drug Discovery programme at Bangalore, engaged in finding a cure for tuberculosis (TB), a disease prevalent in the developing world and making a re-appearance in developed countries.

22 February 2007 
AstraZeneca Announces Investment in $120m Laboratory for Process Research and Development at its Macclesfield Site, Cheshire, UK
This adds to the company’s significant investment in the UK over recent years.

22 January 2007
AstraZeneca Makes $100M Research Investment In Boston
AstraZeneca today announced a $100m research investment to strategically boost work in the infectious disease area and continue its incremental growth in cancer research at its R&D center near Boston, Massachusetts.

1 November 2006
AstraZeneca Appoints Howard Hutchinson as Chief Medical Officer
In his new role, Dr. Hutchinson will provide medical oversight of the early and late stage portfolio in global drug development and act as AstraZeneca’s senior medical representative interacting with medical and industry related organisations.

27 September 2006
AstraZeneca Opens Its First Clinical Pharmacology Unit in the US
This new CPU, located at the University of Pennsylvania Health Care System’s Penn Presbyterian Medical Center, represents a significant investment in research capabilities in the Delaware Valley.   

18 September 2006
AstraZeneca Officially Opens Two Major Scientific Laboratories, As Latest Phase Of UK R&D Investment Programme
These latest developments add to AstraZeneca’s significant investment in the UK, with the creation of over 550 new science-related jobs over the last seven years.  

15 September 2006
AstraZeneca and Schering AG Form Strategic Alliance to Develop Novel SERD Breast Cancer Drug
Under the terms of the agreement, the companies will jointly develop the novel SERD with AstraZeneca leading the clinical development and Schering leading the non-clinical and process development as well as manufacturing activities. 

26 May 2006
AstraZeneca Announces $100 Million R&D Investment in China
The prime focus of this programme will be the establishment of the AstraZeneca Innovation Centre China, which will initially focus on oncology research.   

23 May 2006
"Young Minds in Psychiatry" award winners announced
Six top scientists receive career development support.

17 March 2006
AstraZeneca and University of Pennsylvania School of Medicine to Collaborate on Research
This research collaboration agreement will allow for pre-clinical and clinical research on new treatments for a number of medical conditions.  

12 January 2006 
AstraZeneca And M. D. Anderson Cancer Center Form Umbrella Scientific Collaboration Agreements
The integrated pre-clinical and clinical research on new treatments for cancer, focusing initially on aerodigestive diseases (e.g., lung cancer, head and neck cancers or colorectal cancers).